GSK VS REGN Stock Comparison

Performance

GSK
10/100

GSK returned 3.98% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

REGN
23/100

REGN returned 10.99% in the last 12 months. Based on SPY's performance of 15.09%, its performance is below average giving it a score of 22 of 100.

Analyst Price Targets

GSK
63/100

4 analysts offer 12-month price targets for GSK. Together, they have an average target of 0, the most optimistic target put GSK at 0 within 12-months and the most pessimistic has GSK at 0.

REGN
68/100

26 analysts offer 12-month price targets for REGN. Together, they have an average target of 791.45, the most optimistic target put REGN at 976 within 12-months and the most pessimistic has REGN at 604.

Technicals

GSK
10/100

GSK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

REGN
86/100

REGN receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.

Earnings

GSK
66/100

GSK has missed earnings 3 times in the last 20 quarters.

REGN
100/100

REGN has missed earnings 1 times in the last 20 quarters.

Profit

GSK
72/100

Out of the last 20 quarters, GSK has had 20 profitable quarters and has increased their profits year over year on 7 of them.

REGN
80/100

Out of the last 20 quarters, REGN has had 20 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

GSK
56/100

GSK has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

REGN
57/100

REGN has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

Sentiment

GSK

"Sentiment" not found for GSK

REGN
72/100

REGN had a bullish sentiment score of 72.04% across Twitter and StockTwits over the last 12 months. It had an average of 38.16 posts, 65.65 comments, and 370.30 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

GSK plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / GSK

Healthcare

Drug Manufacturers - General

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Regeneron Pharmaceuticals Inc Summary

Nasdaq / REGN

Healthcare

Biotechnology

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Power up your portfolio